KYO Pharma (NASDAQ:OKYO) reported new exploratory Phase 2a findings for its lead candidate, urcosimod (0.05%), demonstrating that the topical therapy significantly improves the quality of life (QoL) for patients suffering from neuropathic corneal pain (NCP).
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.
General Mills (NYSE:GIS) reported a sharp decline in its third-quarter financial results for the period ended February 22, 2026, as the consumer foods giant navigates a complex portfolio restructuring and rising operational costs.
In times of uncertainty, we often look for something solid to hold onto. Lately, it seems the world’s investors have decided that “something solid” is, quite literally, gold.
The metal’s soaring price is more than just a market trend; it's a global barometer of anxiety.
When faith in currencies, governments, and traditional financial systems begins to waver, we see a familiar flight to the perceived safety of this timeless asset.
Well, pull out the party hats and dust off the stock tickers.
Lithium, the commodity that investors and analysts had all but left for dead in the great market purge of 2023-2024, is back.
The stock market has long treated Tesla (NASDAQ:TSLA) less as a traditional automaker and more as a futuristic technology cult, with its valuation soaring on the gravitational pull of its CEO, Elon Musk.
This persistent "Musk Premium" has burned countless short-sellers.
Bitcoin has vaporised more than US$800 billion in its latest crash and sucked US$1 trillion out of the broader crypto market.
With nearly US$2 trillion in market value and rising allocations from Wall Street firms, ETFs, pension funds, and insurers, Bitcoin is increasingly woven into traditional finance.
Global energy markets are reeling as oil tracks toward its most significant weekly gain in four years, fuelled by escalating conflict in the Middle East.
Global oil prices held steady on March 3 as energy markets braced for an intensification of conflict in the Middle East.
U.S. Customs and Border Protection (CBP) will officially stop collecting billions in trade duties at 12:01 a.m. EST on Tuesday, following a landmark Supreme Court ruling that declared President Donald Trump’s use of emergency powers to levy tariffs illegal.
Jabil (NYSE:JBL) today reported preliminary, unaudited financial results for its second quarter of fiscal year 2026, delivering a performance that exceeded internal guidance and Wall Street consensus.
General Mills (NYSE:GIS) reported a sharp decline in its third-quarter financial results for the period ended February 22, 2026, as the consumer foods giant navigates a complex portfolio restructuring and rising operational costs.
Williams-Sonoma (NYSE:WSM) reported financial results for the fourth quarter and fiscal year ended February 1, 2026, revealing a resilient top line tempered by significant macroeconomic headwinds.
The Trump administration formally defended the Pentagon’s blacklisting of Anthropic in a Tuesday court filing, asserting that the designation of the artificial intelligence firm as a national security threat was both justified and lawful.
Protagonist Therapeutics (NASDAQ:PTGX) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older weighing at least 40 kg.
-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)
